drugset / Trial / NCT00166257
PC-Trial: Patent Foramen Ovale and Cryptogenic Embolism
Phase 4
Unknown
414 enrolled
Foundation for Cardiovascular Research, Zurich
Abbott Medical Devices · collab
RandomizedParallel-groupOpen-labelPrevention
Summary
The purpose of this study is to compare two treatments strategies to prevent further attacks in patients who have suffered an stroke or occlusion of a major artery with no obvious reason other than a persistent small opening between the upper heart chambers
Timeline
- Start
- 2000-02
- Primary completion
- 2011-02
- Completion
- 2011-05
Publications
- Meier B, Kalesan B, Mattle HP, Khattab AA, Hildick-Smith D, Dudek D, Andersen G, Ibrahim R, Schuler G, Walton AS, Wahl A, Windecker S, Juni P; PC Trial Investigators. Percutaneous closure of patent foramen ovale in cryptogenic embolism. N Engl J Med. 2013 Mar 21;368(12):1083-91. doi: 10.1056/NEJMoa1211716.
- Khattab AA, Windecker S, Juni P, Hildick-Smith D, Dudek D, Andersen HR, Ibrahim R, Schuler G, Walton AS, Wahl A, Mattle HP, Meier B. Randomized clinical trial comparing percutaneous closure of patent foramen ovale (PFO) using the Amplatzer PFO Occluder with medical treatment in patients with cryptogenic embolism (PC-Trial): rationale and design. Trials. 2011 Feb 28;12:56. doi: 10.1186/1745-6215-12-56.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aspirin | Small molecule | 100 mg | — |
| Subject | Aspirin | Small molecule | 325 mg | — |
| Subject | Clopidogrel | Small molecule | 75 mg | — |
| Subject | Clopidogrel | Small molecule | 150 mg | — |
| Subject | Warfarin | Small molecule | — | — |